Gufic Biosciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.74×	0.74×	0.74×	0.74×	—
	0.74×	0.72×	0.83×	0.90×	—
	13.6%	12.8%	13.9%	16.0%	—
	0.75×	0.75×	0.72×	0.83×	—
	2.02×	2.02×	1.95×	2.05×	2.48×
	11.3%	10.3%	11.9%	18.2%	—
	10.1%	10.1%	12.3%	19.6%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GUFICBIO₹423.75

Gufic Biosciences Limited

· Pharma & Health

₹ CrorePeersRPGLIFE UNICHEMLAB GUJTHEM ORCHPHARMA SMSPHARMA INDSWFTLAB FDC IOLCPMcap ₹4,249 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	—	0.74	0.74	0.74	0.74
Interest Burden (Pretax/EBIT) ×	—	0.90	0.83	0.72	0.74
EBIT Margin %	—	15.97	13.86	12.77	13.64
Asset Turnover ×	—	0.83	0.72	0.75	0.75
Financial Leverage (Assets/Equity) ×	2.48	2.05	1.95	2.02	2.02
ROE (5-step product, year-end total equity) %	—	18.18	11.90	10.30	11.34
ROE (owners' profit / average owners' equity) %	—	19.57	12.29	10.14	10.14

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.